Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer

Breast cancer is a heterogeneous disease with multiple subgroups based on clinical and molecular characteristics. For the largest subgroup of breast cancers, hormone receptor-positive/human epidermal growth factor 2 (HER2)-negative tumors, hormone treatment is the mainstay of therapy and is likely t...

Descripción completa

Detalles Bibliográficos
Autor principal: Boér, Katalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067010/
https://www.ncbi.nlm.nih.gov/pubmed/27785059
http://dx.doi.org/10.2147/OTT.S77033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067010/
https://www.ncbi.nlm.nih.gov/pubmed/27785059
http://dx.doi.org/10.2147/OTT.S77033

Ejemplares similares